Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

NCT04421963 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04421963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04421963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 4, 2020
Completion date
April 6, 2027
Enrollment
185 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian cancer